Orito E - Search Results

1

Risk of hepatocellular carcinoma in cirrhotic hepatitis B virus patients during nucleoside/nucleotide analog therapy.

Orito E, Hasebe C, Kurosaki M, Osaki Y, Joko K, Watanabe H, Kimura H, Nishijima N, Kusakabe A, Izumi N; Japanese Red Cross Liver Network. Orito E, et al. Hepatol Res. 2015 Aug;45(8):872-9. doi: 10.1111/hepr.12427. Epub 2014 Nov 20. Hepatol Res. 2015. PMID: 25244601

2

Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma.

Takeda H, Nishikawa H, Osaki Y, Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, Izumi N; Japanese Red Cross Liver Study Group. Takeda H, et al. Among authors: orito e. Hepatol Res. 2015 Oct;45(10):E130-40. doi: 10.1111/hepr.12480. Epub 2015 Mar 3. Hepatol Res. 2015. PMID: 25581351

3

A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C.

Orito E, Fujiwara K, Tanaka Y, Yuen MF, Lai CL, Kato T, Sugauchi F, Kusakabe A, Sata M, Okanoue T, Niitsuma H, Sakugawa H, Hasegawa I, Mizokami M. Orito E, et al. Hepatol Res. 2006 Jun;35(2):127-34. doi: 10.1016/j.hepres.2006.03.005. Epub 2006 Apr 19. Hepatol Res. 2006. PMID: 16621686

4

Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.

Takeda H, Nishikawa H, Osaki Y, Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, Izumi N; Japanese Red Cross Liver Study Group. Takeda H, et al. Among authors: orito e. Liver Int. 2015 May;35(5):1581-9. doi: 10.1111/liv.12591. Epub 2014 Jun 10. Liver Int. 2015. PMID: 24836552

5

Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan.

Nishikawa H, Takeda H, Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, Osaki Y, Izumi N; Japanese Red Cross Liver Study Group. Nishikawa H, et al. Among authors: orito e. J Cancer. 2014 Jun 7;5(7):499-509. doi: 10.7150/jca.9257. eCollection 2014. J Cancer. 2014. PMID: 24963354 Free PMC article.

6

Comparison of standard-dose and half‑dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis.

Nishikawa H, Osaki Y, Endo M, Takeda H, Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, Izumi N; Japanese Red Cross Liver Study Group. Nishikawa H, et al. Among authors: orito e. Int J Oncol. 2014 Dec;45(6):2295-302. doi: 10.3892/ijo.2014.2654. Epub 2014 Sep 16. Int J Oncol. 2014. PMID: 25230744

7

Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.

Sakai K, Takeda H, Nishijima N, Orito E, Joko K, Uchida Y, Izumi N, Nishio K, Osaki Y. Sakai K, et al. Among authors: orito e. Oncotarget. 2015 Aug 28;6(25):21636-44. doi: 10.18632/oncotarget.4270. Oncotarget. 2015. PMID: 26046304 Free PMC article.

8

Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma.

Tanaka Y, Mukaide M, Orito E, Yuen MF, Ito K, Kurbanov F, Sugauchi F, Asahina Y, Izumi N, Kato M, Lai CL, Ueda R, Mizokami M. Tanaka Y, et al. Among authors: orito e. J Hepatol. 2006 Nov;45(5):646-53. doi: 10.1016/j.jhep.2006.06.018. Epub 2006 Aug 10. J Hepatol. 2006. PMID: 16935384

9

Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C.

Matsuura K, Watanabe T, Iijima S, Murakami S, Fujiwara K, Orito E, Iio E, Endo M, Kusakabe A, Shinkai N, Miyaki T, Nojiri S, Joh T, Tanaka Y. Matsuura K, et al. Among authors: orito e. Hepatol Res. 2014 Nov;44(12):1208-1216. doi: 10.1111/hepr.12294. Epub 2014 Feb 17. Hepatol Res. 2014. PMID: 24372894

10

T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection.

Ito K, Tanaka Y, Orito E, Sugiyama M, Fujiwara K, Sugauchi F, Kato T, Tokita H, Izumi N, Kato M, Yuen MF, Lai CL, Gish RG, Ueda R, Mizokami M. Ito K, et al. Among authors: orito e. Clin Infect Dis. 2006 Jan 1;42(1):1-7. doi: 10.1086/498522. Epub 2005 Nov 29. Clin Infect Dis. 2006. PMID: 16323084

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

173 results

Search Page